US BARDA commits $51 to $186.6 MIllion to EBS for Next Generation Anthrax Vaccine

Recently there have been criticisms that BARDA has not spent much of the 6 billion dollars set aside for biological and chemical warfare treatments and preventive strategies after 9/11.  In fact, a plan was introduced to transfer some of the monies into other programs.

In good bureaucratic fashion, BARDA responded by spending.  Emergent BioSolutions, aka Bioport, will be the beneficiary of more largesse from the federal government.  BARDA, meanwhile, has demonstrated its commitment to develop a next-generation, recombinant anthrax vaccine despite earlier failures and many millions down the drain in this pursuit during the past ten years.

Here is the agency announcement.